<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vet Sci</journal-id><journal-id journal-id-type="iso-abbrev">Vet Sci</journal-id><journal-id journal-id-type="publisher-id">vetsci</journal-id><journal-title-group><journal-title>Veterinary Sciences</journal-title></journal-title-group><issn pub-type="epub">2306-7381</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40005931</article-id><article-id pub-id-type="pmc">PMC11861717</article-id><article-id pub-id-type="doi">10.3390/vetsci12020170</article-id><article-id pub-id-type="publisher-id">vetsci-12-00170</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Establishment of a Direct Competitive ELISA for Camel FGF21 Detection</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Yuxuan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-vetsci-12-00170" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00170" ref-type="aff">2</xref><xref rid="fn1-vetsci-12-00170" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Hong</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><xref rid="af2-vetsci-12-00170" ref-type="aff">2</xref><xref rid="fn1-vetsci-12-00170" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Jiao</surname><given-names>Yunjuan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><xref rid="af2-vetsci-12-00170" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Shuqin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af1-vetsci-12-00170" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Fu</surname><given-names>Yuanfang</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><xref rid="af2-vetsci-12-00170" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Bai</surname><given-names>Xingwen</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af2-vetsci-12-00170" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Zengjun</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-vetsci-12-00170" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6149-5487</contrib-id><name><surname>Gao</surname><given-names>Yuan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-vetsci-12-00170" ref-type="aff">1</xref><xref rid="c1-vetsci-12-00170" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Bruschetta</surname><given-names>Giuseppe</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vetsci-12-00170"><label>1</label>College of Life Science and Technology, Gansu Agricultural University, Lanzhou 730070, China</aff><aff id="af2-vetsci-12-00170"><label>2</label>Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China</aff><author-notes><corresp id="c1-vetsci-12-00170"><label>*</label>Correspondence: <email>gaoy@gsau.edu.cn</email></corresp><fn id="fn1-vetsci-12-00170"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>14</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>12</volume><issue>2</issue><elocation-id>170</elocation-id><history><date date-type="received"><day>20</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>09</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>11</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract abstract-type="plain-language-summary"><title>Simple Summary</title><p>The camel is an amazing domestic species in arid and semi-arid desert regions, with multiple uses such as transportation, milk, meat, racing, and tourism. Camels can store excess fat in their humps, which enables them to survive in drought and eat less for a long period of time. Fibroblast growth factor (FGF) 21 is a key hormone that regulates metabolic pathways and energy homeostasis. However, the absence of a specific detection method for camel FGF21 impacts research on camels&#x02019; metabolic regulation. This study has established a direct competition ELISA assay for detecting camel FGF21, which would provide a rapid quantitative tool for conducting research on the FGF21 factor in camels.</p></abstract><abstract><title>Abstract</title><p>Camels, with the ability to survive under drought and chronic hunger, developed exceptional efficient lipid reserves and energy substance metabolic characteristics. Fibroblast growth factor (FGF) 21 is a hormone that regulates important metabolic pathways and energy homeostasis. However, the absence of a specific detection method for camel FGF21 impacts research on camels&#x02019; metabolic regulation. This study established a direct competition ELISA assay for detecting camel FGF21. Camel FGF21 antigen was expressed and purified through prokaryotic expression system. Polyclonal antibody was produced and purified via immunizing guinea pigs and affinity chromatography assay. Biotin-labeled FGF21 was synthesized artificially as the competitive antigen. After the determination of optimal conditions, including the working concentrations of the antibody and antigen, blocking solution, dilution buffer, and the competition reaction time, the standard curve with a typical &#x0201c;S&#x0201d; shape was generated using GraphPad Prism. The regression equation was Y = 0.1111 + (X<sup>&#x02212;0.7894</sup>) &#x000d7; (2.162 &#x02212; 0.1111)/(X<sup>&#x02212;0.7894</sup> + 15.76<sup>&#x02212;0.7894</sup>), with the IC<sub>50</sub> 15.59 ng/mL, the limit of detection (LOD) 0.024 ng/mL, the limit of quantification (LOQ) 1.861 ng/mL, and the linear range IC<sub>20</sub>~IC<sub>80</sub> 2.0~119.22 ng/mL. The verification test showed that the recovery rate ranged from 91.34% to 98.9%, and the coefficients of variation for the intra- and inter-plate both were less than 10%, indicating that the ELISA method had high accuracy, good repeatability, and high stability. In addition, this ELISA method had the potential to detect FGF21 secretion levels in other species such as mouse, human, and pig. This study provided a rapid quantitative tool for conducting research on the FGF21 factor in camels.</p></abstract><kwd-group><kwd>camel</kwd><kwd>FGF21</kwd><kwd>prokaryotic expression</kwd><kwd>affinity chromatography purification</kwd><kwd>polyclonal antibody</kwd><kwd>direct competition ELISA</kwd></kwd-group><funding-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>32060783</award-id><award-id>03122071</award-id></award-group><award-group><funding-source>Longyuan Youth Talent Project</funding-source><award-id>LYYC-2024-01</award-id></award-group><funding-statement>This research was funded by the National Natural Science Foundation of China (32060783, 03122071) and a Longyuan Youth Talent Project (LYYC-2024-01).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vetsci-12-00170"><title>1. Introduction</title><p>The camel is a unique domestic species in arid and semi-arid desert regions, with multiple uses such as transportation, milk, meat, racing, and tourism [<xref rid="B1-vetsci-12-00170" ref-type="bibr">1</xref>]. It is widely believed that high blood sugar levels and a high salt diet are important adaptive mechanisms for their survival in environments with extremely hot temperatures, sparse vegetation, and limited food and water resources [<xref rid="B1-vetsci-12-00170" ref-type="bibr">1</xref>,<xref rid="B2-vetsci-12-00170" ref-type="bibr">2</xref>]. Many metabolism-related genes in camels, including insulin signaling pathway regulation, salt metabolism regulation, and repeated genes crucial for sodium reabsorption, showed faster evolution speed than in other artiodactyls [<xref rid="B2-vetsci-12-00170" ref-type="bibr">2</xref>]. Moreover, as the main form of energy storage in mammals, fat oxidation could provide energy and water, enabling animals to survive for a long period without eating. Camels can store excess fat in their humps, which enables them to survive in drought and eat less for a long period [<xref rid="B3-vetsci-12-00170" ref-type="bibr">3</xref>]. Although lipid deposition and mobilization are vital for reproduction, lactation, and environmental adaptation, the knowledge about lipid reserves and application mechanisms of this desert species is still limited.</p><p>Fibroblast growth factor 21 (FGF21) was identified as an essential metabolic regulator in 2005 [<xref rid="B4-vetsci-12-00170" ref-type="bibr">4</xref>]. Unlike the canonical FGF family members&#x02019; acting growth stimulating function, such as mitosis, differentiation, and angiogenesis [<xref rid="B5-vetsci-12-00170" ref-type="bibr">5</xref>], FGF21 exerts as a potent regulator of glucose, lipid, and energy metabolism, but was not observed to be mitogenic [<xref rid="B6-vetsci-12-00170" ref-type="bibr">6</xref>,<xref rid="B7-vetsci-12-00170" ref-type="bibr">7</xref>,<xref rid="B8-vetsci-12-00170" ref-type="bibr">8</xref>]. FGF21 lacks the typical heparan-binding domain that defines the nonendocrine FGFs, which enables its escape from the extracellular matrix into circulation and functions as an endocrine factor [<xref rid="B9-vetsci-12-00170" ref-type="bibr">9</xref>,<xref rid="B10-vetsci-12-00170" ref-type="bibr">10</xref>]. In mammals, FGF21 is expressed in many tissues, including the liver, adipocytes, pancreas, muscle, and central nervous system. Specifically, FGF21 is abundantly expressed in the liver and protects it against steatosis via regulating lipid and free fatty acid metabolism in the liver [<xref rid="B11-vetsci-12-00170" ref-type="bibr">11</xref>]. Additionally, as a promising therapeutic target for metabolism, FGF21 showed the ability to enhance insulin sensitivity, lowing blood glucose and triglyceride (TG) levels, increasing brown adipocyte numbers, preserving &#x003b2;-cell function, inducing sustained weight loss, ameliorating hepatic steatosis, and reducing cardiovascular disease risk [<xref rid="B12-vetsci-12-00170" ref-type="bibr">12</xref>,<xref rid="B13-vetsci-12-00170" ref-type="bibr">13</xref>,<xref rid="B14-vetsci-12-00170" ref-type="bibr">14</xref>,<xref rid="B15-vetsci-12-00170" ref-type="bibr">15</xref>].</p><p>Circulating FGF21 exerts biological functions by binding to the receptor complex, composed of FGF receptor (FGFR) and the co-receptor &#x003b2;-Klotho on the cell surface [<xref rid="B16-vetsci-12-00170" ref-type="bibr">16</xref>,<xref rid="B17-vetsci-12-00170" ref-type="bibr">17</xref>]. Reports have demonstrated that serum FGF21 concentration is elevated in obese humans and is closely related to many metabolic disorder syndromes [<xref rid="B18-vetsci-12-00170" ref-type="bibr">18</xref>]. Moreover, serum level of FGF21 has been suggested as a potential biomarker of many metabolic syndromes, such as type 2 diabetes (T2D), nonalcoholic fatty liver, hyperlipidemia, and cardiovascular diseases [<xref rid="B19-vetsci-12-00170" ref-type="bibr">19</xref>,<xref rid="B20-vetsci-12-00170" ref-type="bibr">20</xref>].</p><p>Enzyme-linked immunosorbent assay (ELISA) is an efficient, sensitive, and commonly used method for detecting circulating protein factors. The commercial ELISA kits for human or mouse FGF21 detection commonly use the double antibody sandwich method, which is characterized by good specificity and high sensitivity. However, this method has high development costs, high detection costs, and robust species specificity. Presently, there is no available test kit for camel FGF21 protein, which poses difficulties for conducting research related to camel FGF21 factor. This study attempted to develop a rapid quantitative detection method for camel serum FGF21 via establishing a direct competitive ELISA detection method based on camel FGF21 polyclonal antibody by immunizing guinea pigs with prokaryotic expression and purification of camel FGF21 protein, which provided a rapid quantitative tool for conducting research on the FGF21 factor in camels.</p></sec><sec id="sec2-vetsci-12-00170"><title>2. Materials and Methods</title><sec id="sec2dot1-vetsci-12-00170"><title>2.1. Bioinformatics Analysis of FGF21 Protein</title><p>Camel, mouse, human, and pig FGF21 gene sequences were obtained from GenBank with accession numbers XM_010996368.1, NM_020013.4, NM_019113.4, and NM_001163410.1, respectively. Signal peptide was analyzed using the SignalP-6.0 network tool (<uri xlink:href="https://services.healthtech.dtu.dk/services/SignalP-6.0/">https://services.healthtech.dtu.dk/services/SignalP-6.0/</uri>, accessed on 4 November 2022). Sequence alignment was performed with CLUSTALW (<uri xlink:href="https://www.genome.jp/tools-bin/clustalw">https://www.genome.jp/tools-bin/clustalw</uri>, accessed on 7 November 2022). Protein spatial structure was predicted using SWISS-MODEL (<uri xlink:href="https://swissmodel.expasy.org/">https://swissmodel.expasy.org/</uri>, accessed on 7 November 2022).</p></sec><sec id="sec2dot2-vetsci-12-00170"><title>2.2. Vector Construction and Protein Expression</title><p>The FGF21 gene, after removing the signal peptide sequence, was cloned into pET-28a (+) plasmid containing His tag. The recombinant vector was introduced into <italic toggle="yes">Escherichia coli</italic> (<italic toggle="yes">E. coli</italic>) Rosetta (DE3) cells (Sangon Biotech, Shanghai, China) for protein expression induced by isopropyl &#x003b2;-D-Thiogalactoside (IPTG, Solarbio, Beijing, China). High-concentration urea was used to denature and dissolve inclusion body proteins. Protein purification was performed using Ni-NTA affinity chromatography (Genscript, Nanjing, China). Target proteins were eluted from a high-concentration imidazolium buffer, and protein renaturation was performed using gradient refolding buffer. Protein purity and specificity were monitored by SDS-PAGE electrophoresis and western blot, respectively.</p></sec><sec id="sec2dot3-vetsci-12-00170"><title>2.3. Preparation of Polyclonal Antibodies Against Camel FGF21 Protein</title><p>Two-month-old guinea pigs with obtained from Experimental Animal Center of Lanzhou Veterinary Research Institute (Lanzhou, China) were employed to generate anti-FGF21 antibodies. Briefly, purified FGF21 protein emulsified with adjuvant Montanide ISA 201 (Seppic, Paris, France) in equal volume was used to produce a vaccine for the immunization of the guinea pigs, with each guinea pig receiving 400 &#x003bc;L (100 &#x003bc;g recombinant protein) intramuscularly on days 0, 21, and 35, respectively. The serum was isolated after cardiac blood collection on day 42. The purification of guinea pig polyclonal antibodies was carried out using the &#x000c4;KTA prime protein purification system and HiTrap Protein A HP antibody purification chromatography (Cytiva, Uppsala, Sweden). Protein purity and specificity were monitored using SDS-PAGE electrophoresis and western blot, respectively.</p></sec><sec id="sec2dot4-vetsci-12-00170"><title>2.4. Preparation of the Biotin-Labeled Antigen</title><p>The Biotin-conjugated camel FGF21 antigen was generated using a Biotin conjugation kit (Sangon Biotech, Shanghai, China) and purified by dialysis using phosphate buffer solution (PBS). Conjugate specificity was monitored by western blot using a horseradish peroxidase (HRP)-conjugated avidin antibody (Genscript, Nanjing, China).</p></sec><sec id="sec2dot5-vetsci-12-00170"><title>2.5. SDS-PAGE Electrophoresis and Western Blot Assay</title><p>Bacterial lysate or purified protein were obtained for SDS-PAGE electrophoresis and western blot detection. Briefly, the protein concentration was determined using a BCA Protein Assay Kit (KeyGen, Nanjing, China). Equal total proteins were separated via 12% SDS-PAGE gel electrophoresis. The protein bands were visualized with Coomassie Brilliant Blue staining (Solarbio, Beijing, China) and decoloration. For the western blot test, gel after electrophoresis was electrotransferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Bedford, MA, USA). After blocking with 10% skimmed milk in TBST for 2 h at room temperature, the membranes were incubated overnight at 4 &#x000b0;C with primary antibodies, including the anti-camel FGF21 polyclonal antibody mentioned above, anti-His tag antibody (CusaBio, Wuhan, China), or anti-human FGF21 antibody (ab171941, Abcam, UK). After three washes with TBST, the membranes were incubated with the corresponding HRP-coupled secondary antibody (CusaBio) for 1 h at 37 &#x000b0;C. Bands were visualized using the Gel Imaging System (Tannon Science &#x00026; Technology, Shanghai, China).</p></sec><sec id="sec2dot6-vetsci-12-00170"><title>2.6. Establishment of Direct Competition ELISA Method</title><p>Polyclonal antibody diluted in 100 &#x003bc;L coating solution was added to each well of the ELISA plate for coating overnight at 4 &#x000b0;C. After washing with PBST 3 times, the plate was blocked with blocking solution of 100 &#x003bc;L in each well at 37 &#x000b0;C for 1 h and then air-dried for later use. We added 50 &#x003bc;L standard protein diluents, with gradient concentrations of 10000, 2000, 400, 80, 16, 3.2, 0.64, and 0.128 ng/mL, or sample to be tested into each well of coating plate together with 50 &#x003bc;L Biotin-camel FGF21 for incubation at 37 &#x000b0;C for 1 h. After washing 3 times with PBST, HRP-conjugated avidin antibody was added into each well and incubated at 37 &#x000b0;C for 30 min. After washing with PBST 5 times, TMB chromogen solution (Beyotime, Beijing, China) was added into each well and maintained for 15 min. After adding stop solution for TMB substrate (Beyotime, Beijing, China) in each well, an OD value of 450 nm wavelength was recorded under the microplate reader. Fitting curves to establish equations of the relationship between the negative logarithm of camel FGF21 antigen content and OD450 value were made using GraphPad Prism 9 software.</p><p>The optimization of reaction conditions for direct competition ELISA was performed based on the maximum OD value (OD<sub>max</sub>), half maximal inhibitory concentration (IC<sub>50</sub>), and OD<sub>max</sub>/IC<sub>50</sub>, including determination of the optimal working concentrations of the encapsulated antibodies (12.5, 10, 7.5, 5 &#x003bc;g/mL) and the enzyme-labeled antigens (20, 15, 10, 5 ng/mL) using a checkerboard titration test, optimization of blocking solution conditions (1% BSA, 2% BSA, 1% BSA 1% sucrose, 1% BSA, 5% sucrose in phosphate buffer), optimization of dilution solution for diluting samples and enzyme-labeled antigens (deionized water, PBST, PBS, 1% BSA), exploring the competitive reaction time at 37 &#x000b0;C (45, 60, 75, and 90 min), and dilution ratio of avidin (1:20,000, 1:25,000, 1:30,000, and 1:35,000).</p></sec><sec id="sec2dot7-vetsci-12-00170"><title>2.7. Determination of Sample Recovery</title><p>Camel FGF21 antibody standards were diluted to different concentrations (3, 18, 50, 120 ng/mL) for the detection and calculation of the recovery rate using the ELISA method established above with the following formula: Recovery = (A/B) &#x000d7; 100%, where A represents the theoretical added concentration and B represents the actual measured concentration.</p><p>The repeatability test of the established ELISA assay was investigated by comparing the IC<sub>50</sub> within and between the batches, and the stability of this method was judged according to the shift deviation of the reaction curve. For the determination of intra-batch stability, random wells of the same plate were selected to measure the concentrations of standards and calculate the coefficient of variation under the optimal detection conditions. For the determination of inter-batch stability, different batches of coated plates were purchased to measure the concentrations of standards and calculate the coefficient of variation under the optimal detection conditions. The coefficient of variation was calculated as the ratio of the standard deviation to the mean.</p></sec><sec id="sec2dot8-vetsci-12-00170"><title>2.8. High-Performance Liquid Chromatography (HPLC) Validation</title><p>An HPLC instrument with a C18 chromatographic column (3 &#x003bc;m, 2.0 mm &#x000d7; 150 mm) was employed to detect the concentrations of camel FGF21 protein samples in the mobile phase of methanol and PBS, with the flow rate 0.6 mL/min, detection wavelength at 280 nm, and injection volume of 20 &#x003bc;L. The ELISA detection results were conducted to be compared with the HPLC results to verify the accuracy and reliability of the ELISA method.</p></sec><sec id="sec2dot9-vetsci-12-00170"><title>2.9. Detection of Reactivity in Species-Specific Reaction</title><p>Mouse FGF21, human FGF21, and pig FGF21 protein concentrations were detected using the established ELISA assay. On the original reaction system, a gradient dilution of the three proteins was used as a standard, and an attempt was made to establish a standard curve for detecting the concentration of FGF21 protein in different species.</p></sec><sec id="sec2dot10-vetsci-12-00170"><title>2.10. Statistical Analysis</title><p>Data are represented as the mean &#x000b1; SEM of repeated experiments. Statistical analyses were performed with one-way ANOVA, followed by Fisher&#x02019;s least significant difference test (Fisher&#x02019;s LSD) and the independent-samples Student&#x02019;s t test with SPSS software (Version 20.0; SPSS, Chicago, IL, USA). <italic toggle="yes">p</italic> &#x0003c; 0.05 was considered significant.</p></sec></sec><sec sec-type="results" id="sec3-vetsci-12-00170"><title>3. Results</title><sec id="sec3dot1-vetsci-12-00170"><title>3.1. FGF21 Protein Is Highly Conserved in Mammals</title><p>To understand the biological characteristics of FGF21 protein, sequence alignment of camel, human, mouse, and pig FGF21 peptides was performed with CLUSTALW, signal peptides were predicted with SignalP, and protein spatial structure was predicted with SWISS-MODEL, respectively. As shown in <xref rid="vetsci-12-00170-f001" ref-type="fig">Figure 1</xref>, the FGF21 protein sequence after removing the signal peptide showed high similarity in mammals, including camels, mice, humans, and pigs (<xref rid="vetsci-12-00170-f001" ref-type="fig">Figure 1</xref>A). As expected, the FGF21 protein spatial structure is also highly similar, which is composed of a spherical domain rich in &#x003b2;-strands and a long C- terminal random coil (<xref rid="vetsci-12-00170-f001" ref-type="fig">Figure 1</xref>B). The result indicated that FGF21 protein is highly conserved, suggesting that FGF21 has important biological functions in mammals.</p></sec><sec id="sec3dot2-vetsci-12-00170"><title>3.2. Expression, Purification, and Validation of Recombinant FGF21 Protein</title><p>To promote research related to camel FGF21 protein, this study constructed FGF21 recombinant vector containing His tag and induced the expression of FGF21 protein in <italic toggle="yes">E. coli</italic>. Protein purification was performed using Ni-NTA affinity chromatography. Protein purity and specificity were monitored using SDS-PAGE electrophoresis and western blot, respectively. As shown in <xref rid="vetsci-12-00170-f002" ref-type="fig">Figure 2</xref>, gel electrophoresis determined that this study obtained four high-purity recombinant protein products with a molecular weight of about 25 kD (<xref rid="vetsci-12-00170-f002" ref-type="fig">Figure 2</xref>A). Western blot detection using anti-His tag antibody and commercial anti-human FGF21 antibody showed that the purified products are recombinant FGF21 protein with His tag, including recombinant camel, mouse, human, and pig FGF21 protein (<xref rid="vetsci-12-00170-f002" ref-type="fig">Figure 2</xref>B,C). Notably, commercial anti-human FGF21 antibody showed high affinity for human and mouse FGF21 protein but low affinity for camel and pig FGF21 protein (<xref rid="vetsci-12-00170-f002" ref-type="fig">Figure 2</xref>C). These results demonstrated that this study obtained high-purity camel, mouse, human, and pig FGF21 recombinant proteins, and FGF21 antibodies have species specificity, indicating that it is of great necessity to prepare camel FGF21 antibody for the development of camel FGF21 detection methods.</p></sec><sec id="sec3dot3-vetsci-12-00170"><title>3.3. Preparation of Guinea-Pig-Derived Camel FGF21 Polyclonal Antibody</title><p>To prepare specific camel FGF21 antibody, guinea pigs were intramuscularly immunized with purified recombinant camel FGF21 protein emulsified with adjuvant on days 0, 21, and 35, respectively. Guinea pigs&#x02019; serum was collected on 42 d post-immunization for antibody purification using Protein A HP affinity chromatography column. Purified antibody was analyzed by SDS-PAGE electrophoresis. Antibody titer was determined by indirect ELISA mediated by camel FGF21 antigen and HRP-labeled goat anti-guinea-pig IgG, and antibody specificity was monitored with western blot. As shown in <xref rid="vetsci-12-00170-f003" ref-type="fig">Figure 3</xref>, only one elution peak appeared during the antibody affinity chromatography purification (<xref rid="vetsci-12-00170-f003" ref-type="fig">Figure 3</xref>A). In addition, gel electrophoresis analysis showed that two bands with molecular weights of about 50 kD and 25 kD, corresponding to the heavy chain and light chain of IgG, were clearly visible (<xref rid="vetsci-12-00170-f003" ref-type="fig">Figure 3</xref>B), which demonstrated that high-purity antibody IgG was obtained in this study. The indirect ELISA result confirmed that purified guinea pig anti-camel FGF21 polyclonal antibody can react with antigen protein, and the effective dilution can reach 1:12 800 (<xref rid="vetsci-12-00170-f003" ref-type="fig">Figure 3</xref>C), indicating that this study obtained high-level production of antibody via the immunization of guinea pigs with purified camel FGF21 recombinant protein. To further determine the species specificity of the antibodies, purified guinea pig IgG was conducted to hybridize with different species&#x02019; FGF21 protein. As shown in <xref rid="vetsci-12-00170-f003" ref-type="fig">Figure 3</xref>D, guinea pig IgG showed a strong affinity with camel and pig FGF21 protein, but a low affinity with human and mouse FGF21 protein, further confirming that FGF21 antibodies have species specificity. All of these results have demonstrated that high-purity and high-specificity guinea pig anti-camel FGF21 polyclonal antibody was obtained in this study.</p></sec><sec id="sec3dot4-vetsci-12-00170"><title>3.4. Preparation and Validation of Biotin-Labeled Antigen</title><p>To assist in establishing an ELISA detection method for camel FGF21 factor, Biotin-labeled camel FGF21 antigen was generated using a Biotin conjugation kit and monitored with HRP-conjugated Biotin antibody-mediated western blot. As shown in <xref rid="vetsci-12-00170-f004" ref-type="fig">Figure 4</xref>, an expected single band above 25 kD was observed on the membrane, indicating that the camel FGF21 protein was successfully labeled with the Biotin tag.</p></sec><sec id="sec3dot5-vetsci-12-00170"><title>3.5. Optimization of Direct Competition ELISA Reaction Conditions</title><p>The determination of optimal conditions is crucial for the establishment of ELISA detection methods. To establish a direct competition ELISA detection method for camel FGF21 factor, the maximum OD value (OD<sub>max</sub>), IC<sub>50</sub>, and OD<sub>max</sub>/IC<sub>50</sub> were used as reference indexes to optimize the reaction conditions and select the best reaction conditions. IC<sub>50</sub> is termed as a 50% binding rate of the OD value of wells with added inhibitory substances B/and the OD value of control wells without added inhibitory substances B<sub>0</sub>. The smaller the IC<sub>50</sub> value is, the stronger the specificity and sensitivity of the reaction.</p><p>The chessboard method was employed to determine the optimal working concentration of encapsulated antibody and Biotin-labeled camel FGF21 antigen. As shown in <xref rid="vetsci-12-00170-t001" ref-type="table">Table 1</xref>, under the filtering conditions of a larger OD<sub>max</sub> value, smaller IC<sub>50</sub> value, and maximal OD<sub>max</sub>/IC<sub>50</sub>, the optimal encapsulated antibody concentration is 10 &#x003bc;g/mL and the optimal Biotin-labeled antigen concentration is 20 ng/mL.</p><p>The blocking solution plays an important role in removing the non-specific binding of antigens and antibodies. Adding sucrose in a blocking solution can reduce the IC<sub>50</sub> value, due to its role as a protective agent to protect the encapsulated proteins in the ELISA plates, although sucrose has no blocking effect. As shown in <xref rid="vetsci-12-00170-f005" ref-type="fig">Figure 5</xref>A, the minimum IC<sub>50</sub> value and maximum OD<sub>max</sub>/IC<sub>50</sub> value can be obtained by using a blocking solution containing 1% BSA 5% sucrose in PBS. Therefore, this solution is determined as the blocking solution of the ELISA reaction system.</p><p>Dilution buffer is another factor that affects ELISA detection sensitivity. As shown in <xref rid="vetsci-12-00170-f005" ref-type="fig">Figure 5</xref>B, dilution buffer of 1% BSA in PBS harvests minimum IC<sub>50</sub> values and maximum OD<sub>max</sub>/IC<sub>50</sub> values. Therefore, 1% BSA in PBS was chosen as the standard dilution.</p><p>To determine the dilution factor of avidin, the gradient dilution of avidin was performed for OD<sub>450</sub> detection to calculate the OD<sub>max</sub>/IC<sub>50</sub> value. As shown in <xref rid="vetsci-12-00170-f005" ref-type="fig">Figure 5</xref>C, the maximum OD<sub>max</sub>/IC<sub>50</sub> value appeared when the dilution ratio of avidin reached 1:25 000, so 1:25000 was considered as the optimal dilution ratio of avidin.</p><p>To determine the competition reaction time, different reaction time ranges of 45 to 90 min were performed for OD<sub>450</sub> detection to calculate the OD<sub>max</sub>/IC<sub>50</sub> value. As shown in <xref rid="vetsci-12-00170-f005" ref-type="fig">Figure 5</xref>D, as the reaction time increases, the IC<sub>50</sub> continuously decreases and the OD<sub>max</sub>/IC<sub>50</sub> value continuously increases, indicating that increasing incubation time is beneficial for full competition and makes detection more sensitive. Therefore, 90 min of incubation was selected as the requirement for competition reaction.</p></sec><sec id="sec3dot6-vetsci-12-00170"><title>3.6. Establishment of Standard Curve</title><p>Based on the optimal reaction conditions of the direct competitive ELISA method established above, this study generated an &#x0201c;S-type&#x0201d; standard curve (<xref rid="vetsci-12-00170-f006" ref-type="fig">Figure 6</xref>). The regression equation is Y = 0.1111 + (X<sup>&#x02212;0.7894</sup>) &#x000d7; (2.162 &#x02212; 0.1111)/(X<sup>&#x02212;0.7894</sup> + 15.76<sup>&#x02212;0.7894</sup>), and the correlation coefficient R<sup>2</sup> is 0.9974.</p><p>According to the optimal reaction conditions, this study determined the parameters of the competitive ELISA method by measuring 21 blank samples, finding that IC<sub>50</sub> is 15.59 ng/mL, the limit of detection (LOD) is 0.024 ng/mL, the limit of quantification (LOQ) is 1.861 ng/mL, and the linear range IC<sub>20</sub>~IC<sub>80</sub> is 2.0~119.22 ng/mL.</p></sec><sec id="sec3dot7-vetsci-12-00170"><title>3.7. Determination of Recovery Rate</title><p>The evaluation of the sample recovery rate is an important indicator for judging whether the ELISA assay is accurate or not [<xref rid="B21-vetsci-12-00170" ref-type="bibr">21</xref>]. This study used the established direct competitive ELISA method to detect standards of different concentrations and calculate the recovery rate. As shown in <xref rid="vetsci-12-00170-t002" ref-type="table">Table 2</xref>. The recovery rate ranged from 91.34% to 98.9% for four different concentrations of standards, indicating that the detection accuracy of this method is very high.</p><p>To further verify the accuracy of the direct competitive ELISA method established in this study, the samples containing camel FGF21 protein were simultaneously detected using HPLC and ELISA. By comparing the HPLC detection values with those from ELISA and calculating the relative deviation (<xref rid="vetsci-12-00170-t002" ref-type="table">Table 2</xref>), it was found that the direct competitive ELISA method established in this study was generally consistent with the HPLC detection results, with a relative deviation of &#x0003c;3.0%, indicating that the ELISA method is reliable and accurate.</p><p>This study further evaluated the intra- and inter-batch stability of this method. As shown in <xref rid="vetsci-12-00170-t003" ref-type="table">Table 3</xref> and <xref rid="vetsci-12-00170-t004" ref-type="table">Table 4</xref>, the standard deviation of the measured sample concentration was small when the concentration ranged from 3 to 120 ng/mL, and the coefficients of variation of the intra-plate duplicate were all less than 10% (<xref rid="vetsci-12-00170-t003" ref-type="table">Table 3</xref>). In addition, the coefficients of inter-batch variation of IC<sub>50</sub> were also less than 10% (<xref rid="vetsci-12-00170-t004" ref-type="table">Table 4</xref>), indicating that the ELISA method established in this study has good repeatability and high stability, which would meet the detection requirements of field samples.</p></sec><sec id="sec3dot8-vetsci-12-00170"><title>3.8. Species Specificity Verification</title><p>To explore the possibility of using this method to detect FGF21 protein concentrations in other species, this study established the standard curves of mouse FGF21, human FGF21, and pig FGF21 based on the optimal reaction conditions. As shown in <xref rid="vetsci-12-00170-f007" ref-type="fig">Figure 7</xref>, the standard curves established with mouse and human FGF21 protein were the &#x0201c;S-type&#x0201d;, similar to that of camel FGF21. The regression equations are Y(mouse) = 0.1069 + (X<sup>&#x02212;0.7974</sup>)&#x000d7; (2.584 &#x02212; 0.1069)/(X<sup>&#x02212;0.7974</sup> + 2.474<sup>&#x02212;0.7974</sup>), R<sup>2</sup> = 0.9995; and Y(human) = 0.1111 + (X<sup>&#x02212;0.7931</sup>) &#x000d7; (2.488 &#x02212; 0.1111)/(X<sup>&#x02212;0.7931</sup> + 1.554<sup>&#x02212;0.7931</sup>), R<sup>2</sup> = 0.9983. Intriguingly, the standard curve established by pig FGF21 protein showed a simple decreasing type, with the regression equation of Y = &#x02212;0.949 + (X<sup>&#x02212;0.2411</sup>) &#x000d7; (2.682 &#x02212; 0.949)/(X<sup>&#x02212;0.2411</sup> + 269.8<sup>&#x02212;0.2411</sup>), R<sup>2</sup> = 0.9988. Notably, all of the R<sup>2</sup> values were greater than 0.998 in three standard curves, indicating that this ELISA method can also detect samples containing mouse, human, or pig FGF21 proteins with a good degree of confidence.</p></sec></sec><sec sec-type="discussion" id="sec4-vetsci-12-00170"><title>4. Discussion</title><p>FGF21 acts as an endocrine modulator in circulation and regulates glucose and lipid metabolism to maintain energy homeostasis in various organizations, especially in the liver, adipose tissues, muscle, and heart, via receptor FGFR1 and co-factor &#x003b2;-Klotho mediated manner [<xref rid="B22-vetsci-12-00170" ref-type="bibr">22</xref>,<xref rid="B23-vetsci-12-00170" ref-type="bibr">23</xref>]. The circulating FGF21 level is closely related to many metabolic disorders and is a potential biomarker for many disease [<xref rid="B20-vetsci-12-00170" ref-type="bibr">20</xref>,<xref rid="B24-vetsci-12-00170" ref-type="bibr">24</xref>,<xref rid="B25-vetsci-12-00170" ref-type="bibr">25</xref>]. Moreover, FGF21 is now a promising therapeutic target for metabolic diseases [<xref rid="B17-vetsci-12-00170" ref-type="bibr">17</xref>,<xref rid="B26-vetsci-12-00170" ref-type="bibr">26</xref>]. Our previous study revealed that camel FGF21 showed a regulatory pattern distinct from that of humans and mice and exhibited stronger metabolic regulation ability [<xref rid="B3-vetsci-12-00170" ref-type="bibr">3</xref>,<xref rid="B27-vetsci-12-00170" ref-type="bibr">27</xref>]. However, the knowledge about the camel-FGF21-mediated regulatory mechanism is still limited, and a specific detection method for the camel FGF21 factor still needs to be established.</p><p>ELISA technology is one of the most rapid and sensitive methods for the detection and quantitation of biomolecules using an enzyme-labeled antibody in biomedical research; moreover, as a mature biological detection method, it has the advantages of high sensitivity and specificity [<xref rid="B28-vetsci-12-00170" ref-type="bibr">28</xref>,<xref rid="B29-vetsci-12-00170" ref-type="bibr">29</xref>,<xref rid="B30-vetsci-12-00170" ref-type="bibr">30</xref>]. The ELISA detection method utilizes antigen&#x02013;antibody reactions to quantitatively or qualitatively detect target substances through enzyme-catalyzed colorimetric reactions. Its application scope covers multiple aspects, such as disease diagnosis, vaccine evaluation, and scientific research. The principle of the direct competition ELISA method is the simultaneous addition of sample antigens (FGF21 protein) and antigens labeled with tags (Biotin-tagged FGF21 protein) to the wells of the microtiter plate to compete for binding to primary antibodies coated on the wells. The more antigens in the sample, the more primary antibodies will bind to the sample antigen. Anti-tag second antibody conjugated to an enzyme is added, followed by a substrate to elicit a chromogenic signal. The concentration of color is inversely proportional to the amount of antigen present in the sample.</p><p>Currently, there are few commercial FGF21 protein detection kits, which are developed based on monoclonal antibodies against specific epitopes of human and mouse FGF21 protein and have species limitations. Additionally, high-performance liquid chromatography (HPLC) can accurately analyze the protein concentration in the sample [<xref rid="B31-vetsci-12-00170" ref-type="bibr">31</xref>]. However, the half-life of the FGF21 protein in vivo is very short. The physical analysis method requires dialysis, purification, ultrafiltration, and other operations on samples, which will affect the accuracy and stability of FGF21 detection. The ELISA method established in this study can complete the detection by only diluting the sample to be tested, which has strong practicability of on-site samples.</p><p>This study purified FGF21 protein and prepared guinea-pig-derived primary antibody. Although FGF21 proteins have high conservatism in mammals, anti-camel FGF21 antibody showed low binding affinity to human and mouse FGF21 proteins, and anti-human FGF21 antibody showed low binding affinity to camel and pig FGF21 proteins. However, our data indicated that the ELISA method established in this study can also be used to detect other mammalian FGF21 samples, including mouse, human, and pig. The establishment of direct competitive ELISA methods fills the gap in the research of the detection of camel FGF21 protein, providing a foundation for further research on camel FGF21 protein function.</p></sec><sec sec-type="conclusions" id="sec5-vetsci-12-00170"><title>5. Conclusions</title><p>This study established a direct competition ELISA assay for detecting camel FGF21 based on artificial Biotin-labeled FGF21 competitive antigen and anti-camel FGF21 polyclonal antibody. After the determination of optimal conditions, including the working concentrations of the antibody and antigen, blocking solution, dilution buffer, and the competition reaction time, the standard curve with a typical &#x0201c;S&#x0201d; shape was generated with the following regression equation: Y = 0.1111 + (X<sup>&#x02212;0.7894</sup>) &#x000d7; (2.162 &#x02212; 0.1111)/(X<sup>&#x02212;0.7894</sup> + 15.76<sup>&#x02212;0.7894</sup>). The IC<sub>50</sub> is 15.59 ng/mL, the LOD is 0.024 ng/mL, the LOQ is 1.861 ng/mL, and the linear range IC<sub>20</sub>~IC<sub>80</sub> is 2.0~119.22 ng/mL. The verification test showed that the recovery rate ranged from 91.34% to 98.9%, and the coefficients of variation for the intra- and inter-plate were both less than 10%, indicating that the ELISA method had high accuracy, good repeatability, and high stability. In addition, this ELISA method had the potential to detect FGF21 secretion levels in other species such as mice, humans, and pigs.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vetsci-12-00170"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vetsci12020170/s1">https://www.mdpi.com/article/10.3390/vetsci12020170/s1</uri>, File S1: The original photos of gel electrophoresis and protein blots.</p><supplementary-material id="vetsci-12-00170-s001" position="float" content-type="local-data"><media xlink:href="vetsci-12-00170-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, H.Y. and Y.G.; methodology, Y.Y.; validation, Y.J. and Y.F.; formal analysis, S.Z.; investigation, X.B.; writing&#x02014;original draft preparation, Y.Y.; writing&#x02014;review and editing, Y.G.; supervision, Z.L.; funding acquisition, Y.G. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The animal study protocol was approved by the Animal Ethical and Welfare Committee of Gansu Agricultural University (Approval No. GSAU-Eth-LST-2021-004, 10 March 2021).</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>All data generated or analyzed during this study are included in this published article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of the data; in the writing of the manuscript; or in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-vetsci-12-00170"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Panigrahi</surname><given-names>M.</given-names></name>
<name><surname>Kumar</surname><given-names>H.</given-names></name>
<name><surname>Saravanan</surname><given-names>K.A.</given-names></name>
<name><surname>Rajawat</surname><given-names>D.</given-names></name>
<name><surname>Nayak</surname><given-names>S.S.</given-names></name>
<name><surname>Ghildiyal</surname><given-names>K.</given-names></name>
<name><surname>Kaisa</surname><given-names>K.</given-names></name>
<name><surname>Parida</surname><given-names>S.</given-names></name>
<name><surname>Bhushan</surname><given-names>B.</given-names></name>
<name><surname>Dutt</surname><given-names>T.</given-names></name>
</person-group><article-title>Trajectory of livestock genomics in South Asia: A comprehensive review</article-title><source>Gene</source><year>2022</year><volume>843</volume><fpage>146808</fpage><pub-id pub-id-type="doi">10.1016/j.gene.2022.146808</pub-id><pub-id pub-id-type="pmid">35973570</pub-id>
</element-citation></ref><ref id="B2-vetsci-12-00170"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ali</surname><given-names>A.</given-names></name>
<name><surname>Baby</surname><given-names>B.</given-names></name>
<name><surname>Vijayan</surname><given-names>R.</given-names></name>
</person-group><article-title>From Desert to Medicine: A Review of Camel Genomics and Therapeutic Products</article-title><source>Front. Genet.</source><year>2019</year><volume>10</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2019.00017</pub-id><pub-id pub-id-type="pmid">30838017</pub-id>
</element-citation></ref><ref id="B3-vetsci-12-00170"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Tang</surname><given-names>H.</given-names></name>
<name><surname>Yan</surname><given-names>M.</given-names></name>
<name><surname>Yong</surname><given-names>F.</given-names></name>
<name><surname>Bai</surname><given-names>X.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
</person-group><article-title>Localization of FGF21 Protein and Lipid Metabolism-Related Genes in Camels</article-title><source>Life</source><year>2023</year><volume>13</volume><elocation-id>432</elocation-id><pub-id pub-id-type="doi">10.3390/life13020432</pub-id><pub-id pub-id-type="pmid">36836789</pub-id>
</element-citation></ref><ref id="B4-vetsci-12-00170"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kharitonenkov</surname><given-names>A.</given-names></name>
<name><surname>DiMarchi</surname><given-names>R.</given-names></name>
</person-group><article-title>Fibroblast growth factor 21 night watch: Advances and uncertainties in the field</article-title><source>J. Intern. Med.</source><year>2017</year><volume>281</volume><fpage>233</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1111/joim.12580</pub-id><pub-id pub-id-type="pmid">27878865</pub-id>
</element-citation></ref><ref id="B5-vetsci-12-00170"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nishimura</surname><given-names>T.</given-names></name>
<name><surname>Nakatake</surname><given-names>Y.</given-names></name>
<name><surname>Konishi</surname><given-names>M.</given-names></name>
<name><surname>Itoh</surname><given-names>N.</given-names></name>
</person-group><article-title>Identification of a novel FGF, FGF-21, preferentially expressed in the liver</article-title><source>Biochim. Et Biophys. Acta</source><year>2000</year><volume>1492</volume><fpage>203</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/S0167-4781(00)00067-1</pub-id></element-citation></ref><ref id="B6-vetsci-12-00170"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>M.C.</given-names></name>
<name><surname>Shiizaki</surname><given-names>K.</given-names></name>
<name><surname>Kuro-o</surname><given-names>M.</given-names></name>
<name><surname>Moe</surname><given-names>O.W.</given-names></name>
</person-group><article-title>Fibroblast growth factor 23 and Klotho: Physiology and pathophysiology of an endocrine network of mineral metabolism</article-title><source>Annu. Rev. Physiol.</source><year>2013</year><volume>75</volume><fpage>503</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1146/annurev-physiol-030212-183727</pub-id><pub-id pub-id-type="pmid">23398153</pub-id>
</element-citation></ref><ref id="B7-vetsci-12-00170"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dolegowska</surname><given-names>K.</given-names></name>
<name><surname>Marchelek-Mysliwiec</surname><given-names>M.</given-names></name>
<name><surname>Nowosiad-Magda</surname><given-names>M.</given-names></name>
<name><surname>Slawinski</surname><given-names>M.</given-names></name>
<name><surname>Dolegowska</surname><given-names>B.</given-names></name>
</person-group><article-title>FGF19 subfamily members: FGF19 and FGF21</article-title><source>J. Physiol. Biochem.</source><year>2019</year><volume>75</volume><fpage>229</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1007/s13105-019-00675-7</pub-id><pub-id pub-id-type="pmid">30927227</pub-id>
</element-citation></ref><ref id="B8-vetsci-12-00170"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Razzaque</surname><given-names>M.S.</given-names></name>
</person-group><article-title>The FGF23-Klotho axis: Endocrine regulation of phosphate homeostasis</article-title><source>Nat. Rev. Endocrinol.</source><year>2009</year><volume>5</volume><fpage>611</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2009.196</pub-id><pub-id pub-id-type="pmid">19844248</pub-id>
</element-citation></ref><ref id="B9-vetsci-12-00170"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kliewer</surname><given-names>S.A.</given-names></name>
<name><surname>Mangelsdorf</surname><given-names>D.J.</given-names></name>
</person-group><article-title>A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21</article-title><source>Cell Metab.</source><year>2019</year><volume>29</volume><fpage>246</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2019.01.004</pub-id><pub-id pub-id-type="pmid">30726758</pub-id>
</element-citation></ref><ref id="B10-vetsci-12-00170"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Babaknejad</surname><given-names>N.</given-names></name>
<name><surname>Nayeri</surname><given-names>H.</given-names></name>
<name><surname>Hemmati</surname><given-names>R.</given-names></name>
<name><surname>Bahrami</surname><given-names>S.</given-names></name>
<name><surname>Esmaillzadeh</surname><given-names>A.</given-names></name>
</person-group><article-title>An Overview of FGF19 and FGF21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity</article-title><source>Horm. Metab. Res. Horm. Und Stoffwechselforschung Horm. Et Metab.</source><year>2018</year><volume>50</volume><fpage>441</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1055/a-0623-2909</pub-id><pub-id pub-id-type="pmid">29883971</pub-id>
</element-citation></ref><ref id="B11-vetsci-12-00170"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Szczepanska</surname><given-names>E.</given-names></name>
<name><surname>Gietka-Czernel</surname><given-names>M.</given-names></name>
</person-group><article-title>FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance</article-title><source>Horm. Metab. Res. Horm. Und Stoffwechselforschung Horm. Et Metab.</source><year>2022</year><volume>54</volume><fpage>203</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1055/a-1778-4159</pub-id><pub-id pub-id-type="pmid">35413740</pub-id>
</element-citation></ref><ref id="B12-vetsci-12-00170"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Palanivel</surname><given-names>R.</given-names></name>
<name><surname>Rai</surname><given-names>E.</given-names></name>
<name><surname>Park</surname><given-names>M.</given-names></name>
<name><surname>Gabor</surname><given-names>T.V.</given-names></name>
<name><surname>Scheid</surname><given-names>M.P.</given-names></name>
<name><surname>Xu</surname><given-names>A.</given-names></name>
<name><surname>Sweeney</surname><given-names>G.</given-names></name>
</person-group><article-title>Adiponectin stimulates autophagy and reduces oxidative stress to enhance insulin sensitivity during high-fat diet feeding in mice</article-title><source>Diabetes</source><year>2015</year><volume>64</volume><fpage>36</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.2337/db14-0267</pub-id><pub-id pub-id-type="pmid">25071026</pub-id>
</element-citation></ref><ref id="B13-vetsci-12-00170"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Lloyd</surname><given-names>D.J.</given-names></name>
<name><surname>Hale</surname><given-names>C.</given-names></name>
<name><surname>Stanislaus</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>M.</given-names></name>
<name><surname>Sivits</surname><given-names>G.</given-names></name>
<name><surname>Vonderfecht</surname><given-names>S.</given-names></name>
<name><surname>Hecht</surname><given-names>R.</given-names></name>
<name><surname>Li</surname><given-names>Y.S.</given-names></name>
<name><surname>Lindberg</surname><given-names>R.A.</given-names></name>
<etal/>
</person-group><article-title>Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice</article-title><source>Diabetes</source><year>2009</year><volume>58</volume><fpage>250</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.2337/db08-0392</pub-id><pub-id pub-id-type="pmid">18840786</pub-id>
</element-citation></ref><ref id="B14-vetsci-12-00170"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>C.L.</given-names></name>
<name><surname>Weston</surname><given-names>J.Y.</given-names></name>
<name><surname>Chadi</surname><given-names>S.A.</given-names></name>
<name><surname>Fazio</surname><given-names>E.N.</given-names></name>
<name><surname>Huff</surname><given-names>M.W.</given-names></name>
<name><surname>Kharitonenkov</surname><given-names>A.</given-names></name>
<name><surname>Koester</surname><given-names>A.</given-names></name>
<name><surname>Pin</surname><given-names>C.L.</given-names></name>
</person-group><article-title>Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice</article-title><source>Gastroenterology</source><year>2009</year><volume>137</volume><fpage>1795</fpage><lpage>1804</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2009.07.064</pub-id><pub-id pub-id-type="pmid">19664632</pub-id>
</element-citation></ref><ref id="B15-vetsci-12-00170"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Planavila</surname><given-names>A.</given-names></name>
<name><surname>Redondo</surname><given-names>I.</given-names></name>
<name><surname>Hondares</surname><given-names>E.</given-names></name>
<name><surname>Vinciguerra</surname><given-names>M.</given-names></name>
<name><surname>Munts</surname><given-names>C.</given-names></name>
<name><surname>Iglesias</surname><given-names>R.</given-names></name>
<name><surname>Gabrielli</surname><given-names>L.A.</given-names></name>
<name><surname>Sitges</surname><given-names>M.</given-names></name>
<name><surname>Giralt</surname><given-names>M.</given-names></name>
<name><surname>van Bilsen</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Fibroblast growth factor 21 protects against cardiac hypertrophy in mice</article-title><source>Nat. Commun.</source><year>2013</year><volume>4</volume><fpage>2019</fpage><pub-id pub-id-type="doi">10.1038/ncomms3019</pub-id><pub-id pub-id-type="pmid">23771152</pub-id>
</element-citation></ref><ref id="B16-vetsci-12-00170"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>X.</given-names></name>
</person-group><article-title>The FGF metabolic axis</article-title><source>Front. Med.</source><year>2019</year><volume>13</volume><fpage>511</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1007/s11684-019-0711-y</pub-id><pub-id pub-id-type="pmid">31495905</pub-id>
</element-citation></ref><ref id="B17-vetsci-12-00170"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>H.</given-names></name>
<name><surname>Yue</surname><given-names>T.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Wu</surname><given-names>W.</given-names></name>
<name><surname>Xu</surname><given-names>S.</given-names></name>
<name><surname>Weng</surname><given-names>J.</given-names></name>
</person-group><article-title>Targeting FGF21 in cardiovascular and metabolic diseases: From mechanism to medicine</article-title><source>Int. J. Biol. Sci.</source><year>2023</year><volume>19</volume><fpage>66</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.7150/ijbs.73936</pub-id><pub-id pub-id-type="pmid">36594101</pub-id>
</element-citation></ref><ref id="B18-vetsci-12-00170"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jelenik</surname><given-names>T.</given-names></name>
<name><surname>Dille</surname><given-names>M.</given-names></name>
<name><surname>Muller-Luhlhoff</surname><given-names>S.</given-names></name>
<name><surname>Kabra</surname><given-names>D.G.</given-names></name>
<name><surname>Zhou</surname><given-names>Z.</given-names></name>
<name><surname>Binsch</surname><given-names>C.</given-names></name>
<name><surname>Hartwig</surname><given-names>S.</given-names></name>
<name><surname>Lehr</surname><given-names>S.</given-names></name>
<name><surname>Chadt</surname><given-names>A.</given-names></name>
<name><surname>Peters</surname><given-names>E.M.J.</given-names></name>
<etal/>
</person-group><article-title>FGF21 regulates insulin sensitivity following long-term chronic stress</article-title><source>Mol. Metab.</source><year>2018</year><volume>16</volume><fpage>126</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.molmet.2018.06.012</pub-id><pub-id pub-id-type="pmid">29980484</pub-id>
</element-citation></ref><ref id="B19-vetsci-12-00170"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qian</surname><given-names>Z.H.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.C.</given-names></name>
<name><surname>Yang</surname><given-names>N.</given-names></name>
<name><surname>Nie</surname><given-names>H.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
<name><surname>Luo</surname><given-names>P.C.</given-names></name>
<name><surname>Wei</surname><given-names>X.X.</given-names></name>
<name><surname>Guan</surname><given-names>Y.Q.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Yan</surname><given-names>J.H.</given-names></name>
<etal/>
</person-group><article-title>Close association between lifestyle and circulating FGF21 levels: A systematic review and meta-analysis</article-title><source>Front. Endocrinol.</source><year>2022</year><volume>13</volume><elocation-id>984828</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2022.984828</pub-id><pub-id pub-id-type="pmid">36093108</pub-id>
</element-citation></ref><ref id="B20-vetsci-12-00170"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Post</surname><given-names>A.</given-names></name>
<name><surname>Dam</surname><given-names>W.A.</given-names></name>
<name><surname>Sokooti</surname><given-names>S.</given-names></name>
<name><surname>Groothof</surname><given-names>D.</given-names></name>
<name><surname>Gloerich</surname><given-names>J.</given-names></name>
<name><surname>van Gool</surname><given-names>A.J.</given-names></name>
<name><surname>Kremer</surname><given-names>D.</given-names></name>
<name><surname>Gansevoort</surname><given-names>R.T.</given-names></name>
<name><surname>van den Born</surname><given-names>J.</given-names></name>
<name><surname>Kema</surname><given-names>I.P.</given-names></name>
<etal/>
</person-group><article-title>Circulating FGF21 Concentration, Fasting Plasma Glucose, and the Risk of Type 2 Diabetes: Results From the PREVEND Study</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2023</year><volume>108</volume><fpage>1387</fpage><lpage>1393</lpage><pub-id pub-id-type="doi">10.1210/clinem/dgac729</pub-id><pub-id pub-id-type="pmid">36533509</pub-id>
</element-citation></ref><ref id="B21-vetsci-12-00170"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kragstrup</surname><given-names>T.W.</given-names></name>
<name><surname>Vorup-Jensen</surname><given-names>T.</given-names></name>
<name><surname>Deleuran</surname><given-names>B.</given-names></name>
<name><surname>Hvid</surname><given-names>M.</given-names></name>
</person-group><article-title>A simple set of validation steps identifies and removes false results in a sandwich enzyme-linked immunosorbent assay caused by anti-animal IgG antibodies in plasma from arthritis patients</article-title><source>Springerplus</source><year>2013</year><volume>2</volume><fpage>263</fpage><pub-id pub-id-type="doi">10.1186/2193-1801-2-263</pub-id><pub-id pub-id-type="pmid">23875127</pub-id>
</element-citation></ref><ref id="B22-vetsci-12-00170"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Keipert</surname><given-names>S.</given-names></name>
<name><surname>Lutter</surname><given-names>D.</given-names></name>
<name><surname>Schroeder</surname><given-names>B.O.</given-names></name>
<name><surname>Brandt</surname><given-names>D.</given-names></name>
<name><surname>St&#x000e5;hlman</surname><given-names>M.</given-names></name>
<name><surname>Schwarzmayr</surname><given-names>T.</given-names></name>
<name><surname>Graf</surname><given-names>E.</given-names></name>
<name><surname>Fuchs</surname><given-names>H.</given-names></name>
<name><surname>de Angelis</surname><given-names>M.H.</given-names></name>
<name><surname>Tsch&#x000f6;p</surname><given-names>M.H.</given-names></name>
<etal/>
</person-group><article-title>Endogenous FGF21-signaling controls paradoxical obesity resistance of UCP1-deficient mice</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>624</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-14069-2</pub-id><pub-id pub-id-type="pmid">32005798</pub-id>
</element-citation></ref><ref id="B23-vetsci-12-00170"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>Z.</given-names></name>
<name><surname>Zhong</surname><given-names>L.</given-names></name>
<name><surname>Lee</surname><given-names>J.T.H.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>D.</given-names></name>
<name><surname>Geng</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Wong</surname><given-names>C.M.</given-names></name>
<name><surname>Xu</surname><given-names>A.</given-names></name>
</person-group><article-title>The FGF21-CCL11 Axis Mediates Beiging of White Adipose Tissues by Coupling Sympathetic Nervous System to Type 2 Immunity</article-title><source>Cell Metab.</source><year>2017</year><volume>26</volume><fpage>493</fpage><lpage>508.e494</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2017.08.003</pub-id><pub-id pub-id-type="pmid">28844880</pub-id>
</element-citation></ref><ref id="B24-vetsci-12-00170"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>S.R.</given-names></name>
<name><surname>Qiu</surname><given-names>Y.F.</given-names></name>
<name><surname>Zhou</surname><given-names>M.B.</given-names></name>
<name><surname>Chen</surname><given-names>M.</given-names></name>
<name><surname>Hu</surname><given-names>Y.</given-names></name>
<name><surname>Hong</surname><given-names>S.Q.</given-names></name>
<name><surname>Jiang</surname><given-names>L.</given-names></name>
<name><surname>Guo</surname><given-names>Y.</given-names></name>
</person-group><article-title>Circulating FGF21 and GDF15 as Biomarkers for Screening, Diagnosis, and Severity Assessment of Primary Mitochondrial Disorders in Children</article-title><source>Front. Pediatr.</source><year>2022</year><volume>10</volume><elocation-id>851534</elocation-id><pub-id pub-id-type="doi">10.3389/fped.2022.851534</pub-id><pub-id pub-id-type="pmid">35498801</pub-id>
</element-citation></ref><ref id="B25-vetsci-12-00170"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Peng</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>S.P.</given-names></name>
<name><surname>Lin</surname><given-names>Y.S.</given-names></name>
<name><surname>Huang</surname><given-names>Y.F.</given-names></name>
<name><surname>Chen</surname><given-names>W.T.</given-names></name>
<name><surname>Bao</surname><given-names>C.H.</given-names></name>
<name><surname>Zhou</surname><given-names>Z.X.</given-names></name>
<name><surname>Lin</surname><given-names>Z.F.</given-names></name>
<name><surname>Chen</surname><given-names>L.M.</given-names></name>
</person-group><article-title>Increased circulating FGF21 level predicts the burden of metabolic demands and risk of vascular diseases in adults with type 2 diabetes</article-title><source>Bmc Endocrine Disorders</source><year>2023</year><volume>23</volume><elocation-id>272</elocation-id><pub-id pub-id-type="doi">10.1186/s12902-023-01523-y</pub-id><pub-id pub-id-type="pmid">38057786</pub-id>
</element-citation></ref><ref id="B26-vetsci-12-00170"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Sun</surname><given-names>T.</given-names></name>
<name><surname>Yu</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Gong</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
</person-group><article-title>FGF21: A Sharp Weapon in the Process of Exercise to Improve NAFLD</article-title><source>Front. Biosci.</source><year>2023</year><volume>28</volume><elocation-id>351</elocation-id><pub-id pub-id-type="doi">10.31083/j.fbl2812351</pub-id></element-citation></ref><ref id="B27-vetsci-12-00170"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yong</surname><given-names>F.</given-names></name>
<name><surname>Yan</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Ji</surname><given-names>W.</given-names></name>
<name><surname>Zhao</surname><given-names>S.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
</person-group><article-title>Analysis of Functional Promoter of Camel FGF21 Gene and Identification of Small Compounds Targeting FGF21 Protein</article-title><source>Vet. Sci.</source><year>2023</year><volume>10</volume><elocation-id>452</elocation-id><pub-id pub-id-type="doi">10.3390/vetsci10070452</pub-id><pub-id pub-id-type="pmid">37505857</pub-id>
</element-citation></ref><ref id="B28-vetsci-12-00170"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tabatabaei</surname><given-names>M.S.</given-names></name>
<name><surname>Ahmed</surname><given-names>M.</given-names></name>
</person-group><article-title>Enzyme-Linked Immunosorbent Assay (ELISA)</article-title><source>Methods Mol. Biol.</source><year>2022</year><volume>2508</volume><fpage>115</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-2376-3_10</pub-id><pub-id pub-id-type="pmid">35737237</pub-id>
</element-citation></ref><ref id="B29-vetsci-12-00170"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aydin</surname><given-names>S.</given-names></name>
</person-group><article-title>A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA</article-title><source>Peptides</source><year>2015</year><volume>72</volume><fpage>4</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.peptides.2015.04.012</pub-id><pub-id pub-id-type="pmid">25908411</pub-id>
</element-citation></ref><ref id="B30-vetsci-12-00170"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>A.V.</given-names></name>
</person-group><article-title>Direct ELISA</article-title><source>Methods Mol. Biol.</source><year>2015</year><volume>1318</volume><fpage>61</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-2742-5_6</pub-id><pub-id pub-id-type="pmid">26160564</pub-id>
</element-citation></ref><ref id="B31-vetsci-12-00170"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dai</surname><given-names>L.</given-names></name>
<name><surname>Yuan</surname><given-names>B.</given-names></name>
<name><surname>Zhang</surname><given-names>B.</given-names></name>
<name><surname>Chen</surname><given-names>W.</given-names></name>
<name><surname>Yuan</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Zhao</surname><given-names>X.</given-names></name>
</person-group><article-title>Gas/Liquid Chromatography-Mass Spectrometry Analysis of Key Functional Substances Regulating Poll Gland Secretion in Male Camels during Seasonal Estrus</article-title><source>Animals</source><year>2023</year><volume>13</volume><elocation-id>2024</elocation-id><pub-id pub-id-type="doi">10.3390/ani13122024</pub-id><pub-id pub-id-type="pmid">37370534</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vetsci-12-00170-f001"><label>Figure 1</label><caption><p>Conservation analysis of FGF21 protein. (<bold>A</bold>) Sequence of camel, human, mouse, and pig FGF21 peptides were aligned with CLUSTALW. (<bold>B</bold>) Spatial structures of camel, human, mouse, and pig FGF21 protein were predicted with SWISS-MODEL, respectively.</p></caption><graphic xlink:href="vetsci-12-00170-g001" position="float"/></fig><fig position="float" id="vetsci-12-00170-f002"><label>Figure 2</label><caption><p>Validation of recombinant FGF21 proteins after purification. (<bold>A</bold>) SDS-PAGE electrophoresis of purified camel, mouse, human, and pig FGF2 proteins. Protein bands were stained with Caumas Brilliant Blue. (<bold>B</bold>) Western blot analysis of purified recombinant proteins using anti-His Tag antibody. (<bold>C</bold>) Western blot analysis of purified recombinant proteins using commercial anti-human FGF21 antibody. M: Protein marker. 1: Recombinant camel FGF21 protein. 2: Recombinant mouse FGF21 protein. 3: Recombinant human FGF21. 4: Recombinant pig FGF21 protein (<xref rid="app1-vetsci-12-00170" ref-type="app">Supplementary File S1</xref>).</p></caption><graphic xlink:href="vetsci-12-00170-g002" position="float"/></fig><fig position="float" id="vetsci-12-00170-f003"><label>Figure 3</label><caption><p>Purification and analysis of guinea pig anti-camel FGF21 polyclonal antibody. (<bold>A</bold>) UV profile during purification of guinea pig IgG using Protein A HP affinity chromatography. (<bold>B</bold>) SDS-PAGE analysis of purified guinea pig IgG. M: Protein marker. 1: Purified guinea pig IgG. (<bold>C</bold>) Antibody titer was determined by indirect ELISA mediated by camel FGF21-encapsulated antigen and HRP-labeled goat anti-guinea-pig IgG. (<bold>D</bold>) Antibody specificity was monitored using western blot. M: Protein marker. 1: Camel FGF21 protein. 2: Mouse FGF21 protein. 3: Human FGF21 protein. 4: Pig FGF21 protein (<xref rid="app1-vetsci-12-00170" ref-type="app">Supplementary File S1</xref>).</p></caption><graphic xlink:href="vetsci-12-00170-g003" position="float"/></fig><fig position="float" id="vetsci-12-00170-f004"><label>Figure 4</label><caption><p>Validation of Biotin-labeled antigen (<xref rid="app1-vetsci-12-00170" ref-type="app">Supplementary File S1</xref>).</p></caption><graphic xlink:href="vetsci-12-00170-g004" position="float"/></fig><fig position="float" id="vetsci-12-00170-f005"><label>Figure 5</label><caption><p>Optimization of direct competition ELISA reaction conditions. (<bold>A</bold>) Screening of the optimal blocking solution. (<bold>B</bold>) Screening of the optimal dilution solution. (<bold>C</bold>) Determination of the optimal dilution factor of avidin. (<bold>D</bold>) Determination of the optimal reaction time.</p></caption><graphic xlink:href="vetsci-12-00170-g005" position="float"/></fig><fig position="float" id="vetsci-12-00170-f006"><label>Figure 6</label><caption><p>Establishment of camel FGF21 detection standard curve.</p></caption><graphic xlink:href="vetsci-12-00170-g006" position="float"/></fig><fig position="float" id="vetsci-12-00170-f007"><label>Figure 7</label><caption><p>Establishment of mouse, human and pig FGF21 detection standard curve.</p></caption><graphic xlink:href="vetsci-12-00170-g007" position="float"/></fig><table-wrap position="float" id="vetsci-12-00170-t001"><object-id pub-id-type="pii">vetsci-12-00170-t001_Table 1</object-id><label>Table 1</label><caption><p>Optimal working concentration of encapsulated antibody and Biotin-labeled camel FGF21 antigen.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Enzyme-Labeled Antigen Concentration</th><th colspan="12" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Coated Antibody Concentration</th></tr><tr><th colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">12.5 &#x003bc;g/mL</th><th colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">10 &#x003bc;g/mL</th><th colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">7.5 &#x003bc;g/mL</th><th colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">5 &#x003bc;g/mL</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC50</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ODmax</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ODmax/IC50</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC50</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ODmax</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ODmax/IC50</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC50</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ODmax</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ODmax/IC50</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC50</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ODmax</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ODmax/IC50</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">20 ng/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">24.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1.73</td><td align="center" valign="middle" rowspan="1" colspan="1">0.071</td><td align="center" valign="middle" rowspan="1" colspan="1">20.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.617</td><td align="center" valign="middle" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" rowspan="1" colspan="1">22.2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.362</td><td align="center" valign="middle" rowspan="1" colspan="1">0.061</td><td align="center" valign="middle" rowspan="1" colspan="1">22.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1.49</td><td align="center" valign="middle" rowspan="1" colspan="1">0.066</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">15 ng/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">22.15</td><td align="center" valign="middle" rowspan="1" colspan="1">1.465</td><td align="center" valign="middle" rowspan="1" colspan="1">0.066</td><td align="center" valign="middle" rowspan="1" colspan="1">17.8</td><td align="center" valign="middle" rowspan="1" colspan="1">1.376</td><td align="center" valign="middle" rowspan="1" colspan="1">0.077</td><td align="center" valign="middle" rowspan="1" colspan="1">19.15</td><td align="center" valign="middle" rowspan="1" colspan="1">1.162</td><td align="center" valign="middle" rowspan="1" colspan="1">0.061</td><td align="center" valign="middle" rowspan="1" colspan="1">18.6</td><td align="center" valign="middle" rowspan="1" colspan="1">1.268</td><td align="center" valign="middle" rowspan="1" colspan="1">0.068</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10 ng/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">25.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1.112</td><td align="center" valign="middle" rowspan="1" colspan="1">0.044</td><td align="center" valign="middle" rowspan="1" colspan="1">15.1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.041</td><td align="center" valign="middle" rowspan="1" colspan="1">0.069</td><td align="center" valign="middle" rowspan="1" colspan="1">17.2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.922</td><td align="center" valign="middle" rowspan="1" colspan="1">0.054</td><td align="center" valign="middle" rowspan="1" colspan="1">19.7</td><td align="center" valign="middle" rowspan="1" colspan="1">0.984</td><td align="center" valign="middle" rowspan="1" colspan="1">0.05</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 ng/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.896</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.024</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.845</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.048</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.756</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.042</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.799</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.045</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vetsci-12-00170-t002"><object-id pub-id-type="pii">vetsci-12-00170-t002_Table 2</object-id><label>Table 2</label><caption><p>Determination of recovery rate.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Theoretical Value (ng/mL) </th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Average Value (ng/mL)</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Recovery Rate</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Relative Deviation</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ELISA</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPLC</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ELISA</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPLC</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">2.74 &#x000b1; 0.20</td><td align="center" valign="middle" rowspan="1" colspan="1">2.80 &#x000b1; 0.10</td><td align="center" valign="middle" rowspan="1" colspan="1">91.33%</td><td align="center" valign="middle" rowspan="1" colspan="1">93.56%</td><td align="center" valign="middle" rowspan="1" colspan="1">2.43%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">17.41 &#x000b1; 0.81</td><td align="center" valign="middle" rowspan="1" colspan="1">17.64 &#x000b1; 0.43</td><td align="center" valign="middle" rowspan="1" colspan="1">96.72%</td><td align="center" valign="middle" rowspan="1" colspan="1">98.02%</td><td align="center" valign="middle" rowspan="1" colspan="1">1.34%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">49.45 &#x000b1; 0.74</td><td align="center" valign="middle" rowspan="1" colspan="1">48.93 &#x000b1; 0.65</td><td align="center" valign="middle" rowspan="1" colspan="1">98.90%</td><td align="center" valign="middle" rowspan="1" colspan="1">97.87%</td><td align="center" valign="middle" rowspan="1" colspan="1">1.04%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">120</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">116.87 &#x000b1; 2.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">116.34 &#x000b1; 0.57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.39%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.95%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.45%</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vetsci-12-00170-t003"><object-id pub-id-type="pii">vetsci-12-00170-t003_Table 3</object-id><label>Table 3</label><caption><p>Intra-batch stability testing.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Theoretical Value (ng/mL)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Average Value (ng/mL)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Coefficient of Variation Within Batches</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Coefficient of Variation Between Batches</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">2.71 &#x000b1; 0.17</td><td align="center" valign="middle" rowspan="1" colspan="1">6.27%</td><td align="center" valign="middle" rowspan="1" colspan="1">8.39%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">17.18 &#x000b1; 0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">5.22%</td><td align="center" valign="middle" rowspan="1" colspan="1">3.25%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">50</td><td align="center" valign="middle" rowspan="1" colspan="1">48.33 &#x000b1; 0.81</td><td align="center" valign="middle" rowspan="1" colspan="1">1.67%</td><td align="center" valign="middle" rowspan="1" colspan="1">2.28%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">120</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">115.67 &#x000b1; 1.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.32%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.69%</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vetsci-12-00170-t004"><object-id pub-id-type="pii">vetsci-12-00170-t004_Table 4</object-id><label>Table 4</label><caption><p>Inter-batch stability testing.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Batches</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub>/(ng/mL)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">R<sup>2</sup></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">15.05</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9995</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">14.94</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9944</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">16.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9985</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">15.27</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9931</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">15.62</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9971</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">16.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9963</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">15.92</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9975</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Average value</td><td align="center" valign="middle" rowspan="1" colspan="1">15.6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9966</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coefficient of variation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.52%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.31%</td></tr></tbody></table></table-wrap></floats-group></article>